Literature DB >> 11675345

Changes in health and disease of the metalloprotease that cleaves von Willebrand factor.

P M Mannucci1, M T Canciani, I Forza, F Lussana, A Lattuada, E Rossi.   

Abstract

Congenital or immunomediated deficiencies of the metalloprotease that cleaves physiologically von Willebrand factor (vWF) reduce or abolish the degradation of ultralarge vWF multimers that cause the formation of intravascular platelet thrombi in patients with thrombotic thrombocytopenic purpura (TTP). There is little knowledge on the behavior of the protease in other physiological and pathologic conditions. Such knowledge is important to evaluate the specificity of low protease plasma levels in the diagnosis of TTP. Using an enzyme immunoassay, the protease was measured in 177 control subjects of different ages, in 26 full-term newborns, and in 69 women during normal pregnancy. Because TTP is often associated with multiorgan involvement and acute phase reactions, clinical models of these pathologic conditions were also investigated, including decompensated liver cirrhosis (n = 42), chronic uremia (n = 63), acute inflammatory states (n = 15), and the preoperative and postoperative states (n = 24). Protease levels were lower in healthy persons older than 65 than in younger persons. They were low in newborns but became normal within 6 months, and they were lower in the last 2 trimesters of pregnancy than in the first. Protease levels were also low in patients with cirrhosis, uremia, and acute inflammation, and they fell in the postoperative period. There was an inverse relation between low protease and high plasma levels of vWF antigen and collagen-binding activity. In conclusion, low plasma levels of the vWF cleaving protease are not a specific beacon of TTP because the protease is also low in several physiological and pathologic conditions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11675345     DOI: 10.1182/blood.v98.9.2730

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  66 in total

1.  The risk of postpolypectomy bleeding during colonoscopy in patients with early liver cirrhosis.

Authors:  Jung Won Jeon; Hyun Phil Shin; Joung Il Lee; Kwang Ro Joo; Kwan Mi Pack; Jae Myung Cha; Jae Jun Park; Jun Uk Lim; Kyuseong Lim
Journal:  Surg Endosc       Date:  2012-05-31       Impact factor: 4.584

2.  Von Willebrand factor antigen and ADAMTS13 activity assay in pregnant women and severe preeclamptic patients.

Authors:  Dandan Zhang; Juan Xiao; Haoliang Huang; Juanjuan Chen; Tao Liu; Zongzhi Yin; Danping Gao; Qiong Liu; Jihui Ai; Suhua Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-12-22

3.  Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo.

Authors:  S G Shelat; P Smith; J Ai; X L Zheng
Journal:  J Thromb Haemost       Date:  2006-08       Impact factor: 5.824

4.  Thrombotic microangiopathy after treatment with bortezomib and dexamethasone in a patient with multiple myeloma.

Authors:  Rena Morita; Satoshi Hashino; Shinichi Shirai; Noriaki Fujita; Masahiro Onozawa; Kaoru Kahata; Takeshi Kondo; Masahiro Imamura; Masahiro Asaka
Journal:  Int J Hematol       Date:  2008-07-19       Impact factor: 2.490

Review 5.  Molecular basis of ADAMTS13 dysfunction in thrombotic thrombocytopenic purpura.

Authors:  Minola Manea; Diana Karpman
Journal:  Pediatr Nephrol       Date:  2008-09-20       Impact factor: 3.714

6.  Why Do We Need ADAMTS13?

Authors:  Han-Mou Tsai
Journal:  Nihon Kessen Shiketsu Gakkai shi       Date:  2005

Review 7.  Pathophysiology of thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Int J Hematol       Date:  2010-01       Impact factor: 2.490

Review 8.  Pivotal role of ADAMTS13 function in liver diseases.

Authors:  Masahito Uemura; Yoshihiro Fujimura; Saiho Ko; Masanori Matsumoto; Yoshiyuki Nakajima; Hiroshi Fukui
Journal:  Int J Hematol       Date:  2010-01       Impact factor: 2.490

9.  Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience.

Authors:  Paul Coppo; Michael Schwarzinger; Marc Buffet; Alain Wynckel; Karine Clabault; Claire Presne; Pascale Poullin; Sandrine Malot; Philippe Vanhille; Elie Azoulay; Lionel Galicier; Virginie Lemiale; Jean-Paul Mira; Christophe Ridel; Eric Rondeau; Jacques Pourrat; Stéphane Girault; Dominique Bordessoule; Samir Saheb; Michel Ramakers; Mohamed Hamidou; Jean-Paul Vernant; Bertrand Guidet; Martine Wolf; Agnès Veyradier
Journal:  PLoS One       Date:  2010-04-23       Impact factor: 3.240

Review 10.  Venous thromboembolism in cirrhosis.

Authors:  Zhineng J Yang; Karen A Costa; Enrico M Novelli; Roy E Smith
Journal:  Clin Appl Thromb Hemost       Date:  2012-10-17       Impact factor: 2.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.